Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Among authors: muscianisi e. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials.
Wei X, Passera A, Muscianisi E, Uhlmann L, Chen L, Moreno SG, Martin R, Vandemeulebroecke M, Keefe D, Ravichandran S, Wozniak MB. Wei X, et al. Among authors: muscianisi e. J Am Acad Dermatol. 2023 Dec;89(6):1285-1287. doi: 10.1016/j.jaad.2023.07.1035. Epub 2023 Aug 12. J Am Acad Dermatol. 2023. PMID: 37579844 Free article. No abstract available.
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study.
Blauvelt A, Pariser DM, Tyring S, Bagel J, Alexis AF, Soung J, Armstrong AW, Muscianisi E, Kianifard F, Steadman J, Sarkar RP, Garcet S, Krueger JG. Blauvelt A, et al. Among authors: muscianisi e. J Dermatol Sci. 2023 Jan;109(1):12-21. doi: 10.1016/j.jdermsci.2023.01.003. Epub 2023 Jan 9. J Dermatol Sci. 2023. PMID: 36690571 Free article. Clinical Trial.
Secukinumab in adult patients with lichen planus: Efficacy and safety results from the randomised, placebo-controlled, proof-of-concept PRELUDE study.
Passeron T, Reinhardt M, Ehst B, Weiss J, Sluzevich J, Sticherling M, Reygagne P, Wohlrab J, Hertl M, Fazel N, Muscianisi E, Fan H, Hampele I, Compagno N. Passeron T, et al. Among authors: muscianisi e. Br J Dermatol. 2024 May 13:ljae181. doi: 10.1093/bjd/ljae181. Online ahead of print. Br J Dermatol. 2024. PMID: 38735684
Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US.
Ingram JR, Bettoli V, Espy JI, Kokolakis G, Martorell A, Villani AP, Wallinger H, Coak E, Kasparek T, Muscianisi E, Richardson C, Kimball AB. Ingram JR, et al. Among authors: muscianisi e. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1597-1605. doi: 10.1111/jdv.18163. Epub 2022 May 9. J Eur Acad Dermatol Venereol. 2022. PMID: 35445469 Free PMC article.
Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis.
Krueger JG, Murrell DF, Garcet S, Navrazhina K, Lee PC, Muscianisi E, Blauvelt A. Krueger JG, et al. Among authors: muscianisi e. J Allergy Clin Immunol. 2021 Mar;147(3):1107-1109.e2. doi: 10.1016/j.jaci.2020.09.021. Epub 2020 Sep 28. J Allergy Clin Immunol. 2021. PMID: 33002515 Free PMC article. Clinical Trial. No abstract available.
21 results